Page 15 - பங்குதாரர் சிறப்பு நிதி News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from பங்குதாரர் சிறப்பு நிதி. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In பங்குதாரர் சிறப்பு நிதி Today - Breaking & Trending Today

Glancy Prongay & Murray LLP :, a Leading Securities Fraud Law Firm, Announces Investigation of Athenex, Inc. (ATNX) on Behalf of Investors


Message :
Required fields
Glancy Prongay & Murray LLP (“GPM”), a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of Athenex, Inc. (“Athenex” or the “Company”) (NASDAQ: ATNX) investors concerning the Company’s possible violations of the federal securities laws.
If you suffered a loss on your Athenex investments or would like to inquire about potentially pursuing claims to recover your loss under the federal securities laws, you can submit your contact information at https://www.glancylaw.com/cases/athenex-inc/. You can also contact Charles H. Linehan, of GPM at 310-201-9150, Toll-Free at 888-773-9224, or via email at [email protected] to learn more about your rights. ....

Bloomberg Businessweek , Charlesh Linehan , Glancy Prongay Murray , Drug Administration , Associated Press , Athenex Inc , Whistleblower Program , Securities Class Action Services , Glancy Prongay , New Drug Application , Complete Response Letter , Oral Paclitaxel , Class Action Services , Wall Street Journal , Financial Times , Business Daily , Attorney Advertising , Inc Stock Exchange , Press Release , Concerning Atnx , தொடர்புடையது ப்ரெஸ் , விசில்ப்ளோவர் ப்ரோக்ர்யாம் , பத்திரங்கள் வர்க்கம் நடவடிக்கை சேவைகள் , புதியது மருந்து விண்ணப்பம் , முழுமை பதில் கடிதம் , வர்க்கம் நடவடிக்கை சேவைகள் ,

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Immunovant, Inc. f/k/a Health Sciences Acquisitions Corporation of Class Action Lawsuit and Upcoming Deadline


(1)
NEW YORK, March 3, 2021 /PRNewswire/ Pomerantz LLP announces that a class action lawsuit has been filed against Immunovant, Inc. f/k/a Health Sciences Acquisitions Corporation ( HSAC , Immunovant , or the Company ) (NASDAQ: IMVT; HSACU; HSAC; and HSACW) and certain of its officers. The class action, filed in the United States District Court for the Eastern District of New York, and docketed under 21-cv-00918, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired Immunovant securities between October 2, 2019 and February 1, 2021, both dates inclusive (the Class Period ), seeking to recover damages caused by Defendants violations of the federal securities laws and to pursue remedies under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 (the Exchange Act ) and Rule 10b-5 promulgated thereunder, against the Company and certain of its top officials. ....

New York , United States , France General , Los Angeles , Abrahaml Pomerantz , Roberts Willoughby , Prnewswire Pomerantz , Immunovant Sciences Ltd , United States District Court , Immunovant Inc , Securities Exchange , Pomerantz Firm , Health Sciences Acquisitions Corporation , Eastern District , Securities Exchange Act , Class Period , Lead Plaintiff , Immunovant Sciences , Legacy Immunovant , புதியது யார்க் , ஒன்றுபட்டது மாநிலங்களில் , பிரான்ஸ் ஜநரல் , லாஸ் ஏஞ்சல்ஸ் , ராபர்ட்ஸ் விருப்பம் , ஒன்றுபட்டது மாநிலங்களில் மாவட்டம் நீதிமன்றம் , பத்திரங்கள் பரிமாற்றம் ,